Cargando…
Precision oncology: as much expectations as limitations
It is encouraging to witness the recent price reduction and expanded access to next generation sequencing platforms, the increasing number of investments and publications on new targets and respective targeted drugs, as well as the worldwide excitement with anti-cancer personalised therapies. This e...
Autores principales: | Vasconcellos, Vitor Fiorin, Colli, Leandro Machado, Awada, Ahmad, de Castro Junior, Gilberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345072/ https://www.ncbi.nlm.nih.gov/pubmed/30679954 http://dx.doi.org/10.3332/ecancer.2018.ed86 |
Ejemplares similares
-
The Ratio of Observed to Expected: How Much of It Is
Unexpected?
por: Chapman, Jens R., et al.
Publicado: (2018) -
Radiotherapy in Current Neuro-Oncology: There Is Still Much to Reveal
por: Ferini, Gianluca, et al.
Publicado: (2021) -
Real World Evidence: Can We Really Expect It to Have Much Influence?
por: Evans, Keith
Publicado: (2019) -
Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015) -
Biobanking in the era of precision oncology
por: Saini, Kamal S., et al.
Publicado: (2015)